1952 Stock Overview
About the company
Everest Medicines Limited, a biopharmaceutical company, engages in discovery, licensing, clinical development, and commercialization of therapies to address critical unmet medical needs in Greater China and other Asia Pacific markets. Its pipeline products include eleven clinical-stage drug candidates for the treatment of oncology, immunology, cardio-renal, and infectious diseases. Everest Medicines Limited was incorporated in 2017 and is headquartered in Shanghai, China.
Capture your thoughts, links and company narrative
Everest Medicines Limited Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||HK$15.44|
|52 Week High||HK$30.50|
|52 Week Low||HK$5.98|
|1 Month Change||-15.54%|
|3 Month Change||-11.16%|
|1 Year Change||-32.43%|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-78.78%|
Recent News & Updates
|1952||HK Biotechs||HK Market|
Return vs Industry: 1952 underperformed the Hong Kong Biotechs industry which returned -10% over the past year.
Return vs Market: 1952 underperformed the Hong Kong Market which returned -8% over the past year.
|1952 Average Weekly Movement||15.8%|
|Biotechs Industry Average Movement||8.8%|
|Market Average Movement||6.9%|
|10% most volatile stocks in HK Market||13.8%|
|10% least volatile stocks in HK Market||3.4%|
Stable Share Price: 1952 is more volatile than 90% of Hong Kong stocks over the past 3 months, typically moving +/- 16% a week.
Volatility Over Time: 1952's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of Hong Kong stocks.
Everest Medicines Limited Fundamentals Summary
|1952 fundamental statistics|
Is 1952 overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|1952 income statement (TTM)|
|Cost of Revenue||CN¥4.65m|
Last Reported Earnings
Dec 31, 2022
Next Earnings Date
|Earnings per share (EPS)||-0.80|
|Net Profit Margin||-1,933.11%|
How did 1952 perform over the long term?See historical performance and comparison